The preliminary clinical experience with laparoscopic duodenojejunal bypass for treatment of type 2 diabetes mellitus in non-morbidly obese patients: the 1-year result in a single institute.
ABSTRACT Although various bariatric surgeries are widely known for their effect of ameliorating type 2 diabetes mellitus (T2DM), there are only a few reports demonstrating the effect of duodenojejunal bypass on T2DM. The aim of this study was to evaluate and report the clinical effects of laparoscopic duodenojejunal bypass (LDJB) in non-morbidly obese patients with T2DM.
Twelve non-morbidly obese patients with T2DM underwent LDJB. Changes in fasting blood glucose, body mass index glycosylated hemoglobin (HbA1c), and dose of antidiabetic medications were recorded prospectively during a 1-year period.
Reduction in HbA1c occurred 3 months after surgery and was maintained up to 1 year, and hyperglycemia was reversed within 1 month after surgery and remained controlled at 12 months. BMI decreased significantly 1 month after surgery and then remained steady through the year. Three patients (25.0 %) stopped antidiabetic medication, seven (58.3 %) patients maintained or decreased doses, and two (16.7 %) increased doses. Seven (58.3 %) patients had a decline in HbA1c.
LDJB demonstrated a glycemic control effect up to 1 year on T2DM in non-morbidly obese patients.